Quick Answer
Clearside Biomedical, Inc. reported Long Term Debt of $3.82 million for the year ending 2019.
- Clearside Biomedical, Inc. showed a decrease of -59.5% in Long Term Debt from 2018 to 2019.
- This data is from Clearside Biomedical, Inc.'s annual report (Form 10-K), filed with the SEC on March 15, 2021.
- XBRL data for this metric is available from 2015 to 2019 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $3.29 million | Q3 2016: $7.49 million | Q1 2017: $6.89 million | Q2 2017: $6.20 million | Q3 2017: $5.50 million | Q1 2018: $4.11 million | Q2 2018: $9.85 million | Q3 2018: $9.91 million | Q1 2019: $8.65 million | Q2 2019: $7.88 million | Q3 2019: $4.33 million | Q2 2020: $496.0 thousand | Q3 2020: $385.0 thousand.
- Over the full 5 years of available data (2015 to 2019), Clearside Biomedical, Inc.'s Long Term Debt has declined by 10.0%.
- Historical annual values: Fiscal year 2019: $3.82 million | Fiscal year 2018: $9.42 million | Fiscal year 2017: $4.81 million | Fiscal year 2016: $7.59 million | Fiscal year 2015: $4.24 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: